Profile data is unavailable for this security.
About the company
Henan Lingrui Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company operates its businesses through two segments. The Pharmaceutical and Health Care segment is mainly engaged in the production and sales of plasters, oral medicines and ointments. The Other segment is mainly engaged in hotel, catering services and others. The Company's main products include Tongluo Qutong Cream, Huoxue Xiaotong Tincture, Zhuanggu Shexiang Pain Relief Cream, Peiyuan Tongnao Capsules, Shenqi Jiangtang Capsules and others. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)3.78bn
- Net income in CNY799.61m
- Incorporated1999
- Employees2.44k
- LocationHenan Lingrui Pharmaceutical Co LtdNo.666, Jiangjun Road, Xinxian CountyXINYANG 465550ChinaCHN
- Phone+86 3 762973569
- Fax+86 3 762987888
- Websitehttps://www.lingrui.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhejiang CONBA Pharmaceutical Co., Ltd. | 6.58bn | 687.99m | 11.51bn | 8.26k | 17.03 | 1.62 | -- | 1.75 | 0.2665 | 0.2665 | 2.54 | 2.80 | 0.6617 | 2.57 | 4.70 | 796,529.00 | 7.13 | 8.51 | 9.65 | 12.74 | 51.88 | 58.64 | 10.77 | 14.12 | 1.38 | -- | 0.0532 | 41.54 | -3.23 | -0.7594 | 5.21 | -- | 1.57 | -- |
| Cansino Biologics Inc | 971.83m | -142.03m | 11.52bn | 1.11k | -- | 3.05 | -- | 11.86 | -0.5455 | -0.5455 | 3.92 | 21.37 | 0.1271 | 0.5861 | 1.38 | 879,482.50 | -1.86 | -4.08 | -2.29 | -5.38 | 78.80 | 45.31 | -14.62 | -27.51 | 3.29 | -- | 0.2242 | -- | 137.01 | 226.43 | 74.45 | -- | 31.38 | -- |
| Chengdu Easton Biopharmaceuticals Co Ltd | 1.33bn | 241.37m | 11.69bn | 1.52k | 48.24 | 4.08 | -- | 8.80 | 1.37 | 1.37 | 7.55 | 16.23 | 0.3809 | 1.83 | 5.89 | 873,161.50 | 6.92 | 8.09 | 8.44 | 9.82 | 71.90 | 81.72 | 18.16 | 20.10 | 3.12 | -- | 0.0444 | 30.37 | 20.82 | 7.34 | 5.15 | 17.01 | 4.24 | -- |
| Jiangxi Tianxin Pharmaceutical Co Ltd | 2.23bn | 617.04m | 11.89bn | 2.68k | 19.18 | 2.48 | -- | 5.34 | 1.42 | 1.42 | 5.11 | 10.93 | 0.3973 | 2.43 | 9.65 | 830,883.10 | 11.01 | 17.10 | 11.88 | 21.16 | 43.04 | 42.99 | 27.72 | 30.12 | 4.31 | -- | 0.0721 | 24.41 | 17.35 | 1.75 | 36.85 | -2.20 | 35.06 | -- |
| Mayinglong Pharmaceutical Group Co Ltd | 3.77bn | 571.60m | 12.04bn | 2.65k | 21.06 | 2.80 | -- | 3.19 | 1.33 | 1.33 | 8.75 | 9.97 | 0.7211 | 6.23 | 11.99 | 1,421,812.00 | 11.38 | 10.77 | 13.82 | 13.35 | 46.77 | 42.40 | 15.78 | 14.39 | 4.58 | -- | 0.0226 | 37.31 | 18.85 | 6.62 | 19.14 | 7.97 | 34.47 | 18.98 |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | 9.84bn | 546.80m | 12.59bn | 7.99k | 21.98 | 1.48 | -- | 1.28 | 0.4778 | 0.4778 | 8.61 | 7.10 | 0.623 | 3.08 | 5.32 | 1,230,310.00 | 3.48 | 2.33 | 5.81 | 4.32 | 46.64 | 41.26 | 5.58 | 3.99 | 0.6646 | 5.33 | 0.2803 | 29.47 | -5.65 | -2.44 | 745.24 | 45.22 | -26.03 | 33.24 |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.78bn | 799.61m | 12.61bn | 2.44k | 15.78 | 3.88 | -- | 3.33 | 1.41 | 1.41 | 6.67 | 5.73 | 0.711 | 1.89 | 8.06 | 1,553,625.00 | 15.08 | 11.90 | 25.52 | 18.89 | 79.26 | 74.36 | 21.21 | 16.46 | 0.9053 | -- | 0.1379 | 73.97 | 5.72 | 10.17 | 27.19 | 19.67 | 14.29 | 24.57 |
| Shenzhen Chipscreen Biosciences Co Ltd | 850.99m | 7.28m | 12.65bn | 1.06k | 1,735.87 | 7.64 | -- | 14.87 | 0.0179 | 0.0179 | 2.09 | 4.06 | 0.2441 | 2.40 | 4.06 | 802,822.70 | 0.2089 | 0.0036 | 0.2479 | 0.0042 | 85.48 | 91.31 | 0.8557 | 0.0181 | 1.79 | -0.6319 | 0.4834 | 0.00 | 25.63 | 30.51 | -228.97 | -- | 15.08 | -- |
| Beijing Foyou Pharma Co Ltd | 3.42bn | 463.07m | 12.77bn | 3.64k | 26.97 | 3.38 | -- | 3.73 | 0.9863 | 0.9863 | 7.28 | 7.87 | 0.733 | 3.27 | 9.59 | 938,316.50 | 9.99 | 12.53 | 12.82 | 17.64 | 65.17 | 68.01 | 13.62 | 13.02 | 2.52 | -- | 0.0077 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
Data as of Feb 06 2026. Currency figures normalised to Henan Lingrui Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
17.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2025 | 35.96m | 6.36% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 13.54m | 2.39% |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2025 | 11.56m | 2.04% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 9.16m | 1.62% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 7.49m | 1.32% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 7.17m | 1.27% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 4.32m | 0.76% |
| Taikang Asset Management Co. Ltd.as of 30 Jun 2025 | 3.61m | 0.64% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 3.02m | 0.53% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 2.37m | 0.42% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
